Intuitive Surgical, Inc. $ISRG Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lowered its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 145,568 shares of the medical equipment provider’s stock after selling 6,514 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Intuitive Surgical were worth $81,806,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the stock. SteelPeak Wealth LLC lifted its holdings in Intuitive Surgical by 28.7% in the third quarter. SteelPeak Wealth LLC now owns 41,993 shares of the medical equipment provider’s stock worth $18,781,000 after acquiring an additional 9,364 shares during the last quarter. Atlantic Union Bankshares Corp raised its position in shares of Intuitive Surgical by 19.3% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 22,759 shares of the medical equipment provider’s stock worth $10,179,000 after purchasing an additional 3,676 shares during the period. World Investment Advisors raised its position in shares of Intuitive Surgical by 238.3% during the 3rd quarter. World Investment Advisors now owns 5,399 shares of the medical equipment provider’s stock worth $2,415,000 after purchasing an additional 3,803 shares during the period. Valley Wealth Managers Inc. grew its position in shares of Intuitive Surgical by 52.7% during the third quarter. Valley Wealth Managers Inc. now owns 4,084 shares of the medical equipment provider’s stock worth $1,826,000 after acquiring an additional 1,409 shares during the last quarter. Finally, E. Ohman J or Asset Management AB boosted its stake in Intuitive Surgical by 4.1% during the 3rd quarter. E. Ohman J or Asset Management AB now owns 28,306 shares of the medical equipment provider’s stock valued at $12,659,000 after purchasing an additional 1,123 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical Stock Performance

Intuitive Surgical stock opened at $460.99 on Wednesday. The company has a 50 day moving average price of $491.53 and a 200 day moving average price of $513.74. Intuitive Surgical, Inc. has a 52 week low of $425.00 and a 52 week high of $603.88. The firm has a market capitalization of $163.71 billion, a price-to-earnings ratio of 58.43, a P/E/G ratio of 3.49 and a beta of 1.66.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, January 22nd. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.26. The company had revenue of $2.87 billion for the quarter, compared to the consensus estimate of $2.72 billion. Intuitive Surgical had a net margin of 28.38% and a return on equity of 15.06%. The company’s revenue was up 18.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.21 EPS. Equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on ISRG. BTIG Research reaffirmed a “buy” rating and issued a $616.00 price objective on shares of Intuitive Surgical in a report on Friday, January 23rd. Royal Bank Of Canada upped their price target on shares of Intuitive Surgical from $625.00 to $650.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Barclays set a $712.00 price objective on shares of Intuitive Surgical and gave the company an “overweight” rating in a report on Monday, January 26th. Zacks Research upgraded shares of Intuitive Surgical from a “hold” rating to a “strong-buy” rating in a research report on Thursday, February 19th. Finally, Truist Financial upped their price target on shares of Intuitive Surgical from $620.00 to $650.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and an average target price of $614.95.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Analyst/technical optimism: Commentary noting ISRG is technically oversold and that Wall Street estimate revisions are tilting upward is supporting a near-term bounce and buy-the-dip demand. Down 10.1% in 4 Weeks, Here’s Why Intuitive Surgical (ISRG) Looks Ripe for a Turnaround
• Positive Sentiment: Fundamentals remain supportive: Intuitive posted an EPS and revenue beat in its latest quarter with healthy margins and double‑digit revenue growth year-over-year — this gives investors confidence that demand for robot-assisted procedures and consumables can reaccelerate. (See company reports and recent earnings commentary.)
• Neutral Sentiment: Market recap: Recent news pieces note ISRG rose but still lagged the broader market on the session, reflecting mixed investor appetite versus larger-cap growth peers. Intuitive Surgical, Inc. (ISRG) Rises But Trails Market: What Investors Should Know
• Neutral Sentiment: Sector/peer headlines may influence sentiment: Big moves in med‑tech peers (large drawdowns at some names and product launches at others) are creating rotation and headline-driven volatility that can impact ISRG. Examples include coverage of Boston Scientific’s selloff and Baxter’s new IV labeling system. Can Boston Scientific Stock Surge 40% From Here? Baxter International Unveils IV Verify to Enhance IV Labeling Accuracy
• Negative Sentiment: Technical and momentum concerns remain: ISRG has been through a recent pullback (50‑day moving average below the 200‑day) and a multi-week decline that could keep downside risk elevated if procedure volumes or guidance disappoint. Investors should watch upcoming volumes, guidance, and margin commentary closely.

Insider Activity at Intuitive Surgical

In related news, SVP Patricia L. Wadors sold 220 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $499.71, for a total transaction of $109,936.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Mark Brosius sold 645 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $485.01, for a total transaction of $312,831.45. Following the transaction, the senior vice president directly owned 1,613 shares in the company, valued at $782,321.13. The trade was a 28.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 32,943 shares of company stock valued at $17,279,568 over the last ninety days. 0.60% of the stock is owned by company insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.